Investigation
Do pharmaceutical companies suppress inexpensive universal cures because chronic treatment is more profitable?
NCI treatment programs and designated cancer centers document a distributed public and academic research infrastructure pursuing many treatment approaches; this does not eliminate conflicts of interest but raises the evidentiary burden for a coordinated universal-cure suppression claim.